These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3805726)

  • 1. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
    Livingston PO; Calves MJ; Natoli EJ
    J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
    Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
    Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
    Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
    J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO
    Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity.
    Natoli EJ; Livingston PO; Pukel CS; Lloyd KO; Wiegandt H; Szalay J; Oettgen HF; Old LJ
    Cancer Res; 1986 Aug; 46(8):4116-20. PubMed ID: 3731079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
    Ohta S; Igarashi S; Honda A; Sato S; Hanai N
    Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
    Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
    Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific serological response by active immunization with GD3-bearing liposomes.
    Massó O; Aliño SF; Lejarreta M; Blasco F; Piulats J
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1114-20. PubMed ID: 8819493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
    Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
    Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
    Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
    Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
    Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Camplyobacter jejuni.
    Ritter G; Fortunato SR; Cohen L; Noguchi Y; Bernard EM; Stockert E; Old LJ
    Int J Cancer; 1996 Apr; 66(2):184-90. PubMed ID: 8603809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
    Livingston PO; Ritter G; Calves MJ
    Cancer Immunol Immunother; 1989; 29(3):179-84. PubMed ID: 2731184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
    Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental and clinical studies with active specific immunotherapy.
    Livingston PO
    Prog Clin Biol Res; 1989; 288():309-21. PubMed ID: 2654953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.